Cargando…
Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset
INTRODUCTION: We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib. METHODS: This is a non-interventional, cross-sectional, questionnaire based telephonic study which included...
Autores principales: | Chebbi, Pramod, Shobha, Vineeta, Rao, Vijay K, Haridas, Vikram, Janardana, Ramya, Pinto, Benzeeta, Kumar, Sharath, Patil, Abhishek, Tekkatte, Roopa, Salanke, Manasa, Mahendranath, K M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369741/ https://www.ncbi.nlm.nih.gov/pubmed/37496101 http://dx.doi.org/10.1186/s41927-023-00345-8 |
Ejemplares similares
-
Comparison of Risk Factors During First and Second Wave of COVID-19 in Patients with Autoimmune Rheumatic Diseases (AIRD): Results from KRACC Subset
por: Jain, Vikramraj, et al.
Publicado: (2023) -
A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases
por: Patil, Abhishek, et al.
Publicado: (2022) -
Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital
por: Kodali, Ramya, et al.
Publicado: (2022) -
Evaluation of Nematicidal Activity of Streptomyces yatensis KRA-28 against Meloidogyne incognita
por: Park, Eun-Jae, et al.
Publicado: (2020) -
Phylogenetic evidence reveals early Kra-Dai divergence and dispersal in the late Holocene
por: Tao, Yuxin, et al.
Publicado: (2023)